Merck’s attempt to see if Zetia can reduce the growth of coronary plaques blows up in their face. Drs. Wes and Centor (also here), Derek Lowe, #1 Dinosaur, and Health Care Renewal comment on the much-publicized study.
Related posts:
- Zetia: What to tell patients
- Niacin beats Zetia in the ARBITER 6-HALTS trial, and what this means for ezetimibe
- Black Monday for Pfizer?
- The Exubera autopsy
- ENHANCE and Zetia
- FDA cool on rimonabant?
- European drug research
KevinMD.com on Facebook
Comments on this entry are closed.